

# Evan Bloch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1524317/publications.pdf>

Version: 2024-02-01

150  
papers

5,324  
citations

136950

32  
h-index

114465

63  
g-index

172  
all docs

172  
docs citations

172  
times ranked

8620  
citing authors

#	ARTICLE	IF	CITATIONS
1	Deployment of convalescent plasma for the prevention and treatment of COVID-19. Journal of Clinical Investigation, 2020, 130, 2757-2765.	8.2	649
2	A Literature Review of Zika Virus. Emerging Infectious Diseases, 2016, 22, 1185-1192.	4.3	418
3	Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. Journal of Clinical Investigation, 2020, 130, 6141-6150.	8.2	375
4	SARS-CoV-2â€“specific CD8+ T cell responses in convalescent COVID-19 individuals. Journal of Clinical Investigation, 2021, 131, .	8.2	213
5	Early Outpatient Treatment for Covid-19 with Convalescent Plasma. New England Journal of Medicine, 2022, 386, 1700-1711.	27.0	194
6	Comparative Performance of Five Commercially Available Serologic Assays To Detect Antibodies to SARS-CoV-2 and Identify Individuals with High Neutralizing Titers. Journal of Clinical Microbiology, 2021, 59, .	3.9	170
7	Prevention of transfusion-transmitted infections. Blood, 2019, 133, 1854-1864.	1.4	164
8	Blood Transfusion Safety in Africa: A Literature Review of Infectious Disease and Organizational Challenges. Transfusion Medicine Reviews, 2012, 26, 164-180.	2.0	136
9	ABO blood group and COVIDâ€™19: a review on behalf of the ISBT COVIDâ€™19 Working Group. Vox Sanguinis, 2021, 116, 849-861.	1.5	108
10	SARS-CoV-2 Antibody Avidity Responses in COVID-19 Patients and Convalescent Plasma Donors. Journal of Infectious Diseases, 2020, 222, 1974-1984.	4.0	96
11	Metabolic programs define dysfunctional immune responses in severe COVID-19 patients. Cell Reports, 2021, 34, 108863.	6.4	92
12	CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants. Open Forum Infectious Diseases, 2021, 8, ofab143.	0.9	83
13	Genomic Epidemiology Reconstructs the Introduction and Spread of Zika Virus in Central America and Mexico. Cell Host and Microbe, 2018, 23, 855-864.e7.	11.0	82
14	Blood transfusion safety in subâ€™Saharan Africa: A literature review of changes and challenges in the 21st century. Transfusion, 2019, 59, 412-427.	1.6	72
15	The third described case of transfusionâ€™transmitted <i>Babesia duncani</i> . Transfusion, 2012, 52, 1517-1522.	1.6	71
16	Minimal Crossover between Mutations Associated with Omicron Variant of SARS-CoV-2 and CD8 <sup>+</sup> T-Cell Epitopes Identified in COVID-19 Convalescent Individuals. MBio, 2022, 13, e0361721.	4.1	67
17	Persistence of Babesia microti Infection in Humans. Pathogens, 2019, 8, 102.	2.8	61
18	Antibody responses to endemic coronaviruses modulate COVID-19 convalescent plasma functionality. Journal of Clinical Investigation, 2021, 131, .	8.2	58

#	ARTICLE	IF	CITATIONS
19	Markers of Polyfunctional SARS-CoV-2 Antibodies in Convalescent Plasma. MBio, 2021, 12, .	4.1	57
20	The Use of Rapid Diagnostic Tests for Transfusion Infectious Screening in Africa: A Literature Review. Transfusion Medicine Reviews, 2015, 29, 35-44.	2.0	49
21	Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-income countries. Vox Sanguinis, 2021, 116, 18-35.	1.5	48
22	Evaluation of Serological SARS-CoV-2 Lateral Flow Assays for Rapid Point-of-Care Testing. Journal of Clinical Microbiology, 2021, 59, .	3.9	46
23	Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Medicine, 2021, 18, e1003872.	8.4	43
24	Zika Virus and the Blood Supply: What Do We Know?. Transfusion Medicine Reviews, 2017, 31, 1-10.	2.0	42
25	Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern. Blood Advances, 2022, 6, 3678-3683.	5.2	42
26	Development of a real-time polymerase chain reaction assay for sensitive detection and quantitation of <i>Babesia microti</i> infection. Transfusion, 2013, 53, 2299-2306.	1.6	41
27	Cytokine and Chemokine Levels in Coronavirus Disease 2019 Convalescent Plasma. Open Forum Infectious Diseases, 2021, 8, ofaa574.	0.9	41
28	Transfusion-Associated Microchimerism: The Hybrid Within. Transfusion Medicine Reviews, 2013, 27, 10-20.	2.0	40
29	COVID-19 convalescent plasma: Interim recommendations from the AABB. Transfusion, 2021, 61, 1313-1323.	1.6	40
30	How did we rapidly implement a convalescent plasma program?. Transfusion, 2020, 60, 1348-1355.	1.6	40
31	Determination of <i>Babesia microti</i> seroprevalence in blood donor populations using an investigational enzyme immunoassay. Transfusion, 2014, 54, 2237-2244.	1.6	37
32	Pathogen reduction and blood transfusion safety in Africa: strengths, limitations and challenges of implementation in low-resource settings. Vox Sanguinis, 2018, 113, 3-12.	1.5	37
33	Sociodemographic and behavioral characteristics associated with blood donation in the United States: a population-based study. Transfusion, 2019, 59, 2899-2907.	1.6	37
34	A pilot external quality assurance study of transfusion screening for HIV, HCV and HBsAG in 12 African countries. Vox Sanguinis, 2014, 107, 333-342.	1.5	35
35	Motivators and deterrents to blood donation among Black South Africans: a qualitative analysis of focus group data. Transfusion Medicine, 2015, 25, 249-258.	1.1	34
36	Implementation of secondary bacterial culture testing of platelets to mitigate residual risk of septic transfusion reactions. Transfusion, 2018, 58, 1647-1653.	1.6	34

#	ARTICLE	IF	CITATIONS
37	Serologic screening of United States blood donors for <i>Babesia microti</i> using an investigational enzyme immunoassay. <i>Transfusion</i> , 2016, 56, 1866-1874.	1.6	31
38	Convalescent plasma to treat COVID-19. <i>Blood</i> , 2020, 136, 654-655.	1.4	31
39	Costs, consequences, and cost-effectiveness of strategies for <i>Babesia microti</i> donor screening of the US blood supply. <i>Transfusion</i> , 2014, 54, 2245-2257.	1.6	30
40	Clinical use of Convalescent Plasma in the COVID-19 pandemic: a transfusion-focused gap analysis with recommendations for future research priorities. <i>Vox Sanguinis</i> , 2021, 116, 88-98.	1.5	30
41	Revisiting Blood Safety Practices Given Emerging Data about Zika Virus. <i>New England Journal of Medicine</i> , 2018, 378, 1837-1841.	27.0	28
42	Hemostatic properties of cold-stored whole blood leukoreduced using a platelet-sparing versus a non-platelet-sparing filter. <i>Transfusion</i> , 2019, 59, 1809-1817.	1.6	28
43	Promoting access to COVID-19 convalescent plasma in low- and middle-income countries. <i>Transfusion and Apheresis Science</i> , 2021, 60, 102957.	1.0	28
44	Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers. <i>Journal of Clinical Virology</i> , 2021, 145, 104997.	3.1	28
45	Boosting of cross-reactive antibodies to endemic coronaviruses by SARS-CoV-2 infection but not vaccination with stabilized spike. <i>ELife</i> , 2022, 11, .	6.0	26
46	Association of blood donation with iron deficiency among adolescent and adult females in the United States: a nationally representative study. <i>Transfusion</i> , 2019, 59, 1723-1733.	1.6	25
47	Reasons for blood donation deferral in sub-Saharan Africa: experience in Ivory Coast. <i>Transfusion</i> , 2012, 52, 1602-1606.	1.6	22
48	Fatal Transplant-Associated West Nile Virus Encephalitis and Public Health Investigation—California, 2010. <i>Transplantation</i> , 2013, 96, 463-468.	1.0	22
49	ABO blood group and SARS-CoV-2 antibody response in a convalescent donor population. <i>Vox Sanguinis</i> , 2021, 116, 766-773.	1.5	22
50	Medical and economic implications of strategies to prevent alloimmunization in sickle cell disease. <i>Transfusion</i> , 2017, 57, 2267-2276.	1.6	21
51	Financial impact of alternative approaches to reduce bacterial contamination of platelet transfusions. <i>Transfusion</i> , 2019, 59, 1291-1299.	1.6	21
52	A prospective evaluation of chronic <i>Babesia microti</i> infection in seroreactive blood donors. <i>Transfusion</i> , 2016, 56, 1875-1882.	1.6	20
53	Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis. <i>Chimerism</i> , 2011, 2, 6-10.	0.7	19
54	The epidemiology of bacterial culture-positive and septic transfusion reactions at a large tertiary academic center: 2009 to 2016. <i>Transfusion</i> , 2018, 58, 1933-1939.	1.6	19

#	ARTICLE	IF	CITATIONS
55	Screening for transfusion transmissible infections using rapid diagnostic tests in Africa: a potential hazard to blood safety?. <i>Vox Sanguinis</i> , 2016, 110, 196-198.	1.5	18
56	Antibiotic Resistance in Young Children in Kilosa District, Tanzania 4 Years after Mass Distribution of Azithromycin for Trachoma Control. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 815-818.	1.4	18
57	Teenage Blood Donors: Are We Asking Too Little and Taking Too Much?. <i>Pediatrics</i> , 2017, 139, .	2.1	17
58	Use of Blood Donor Screening to Monitor Prevalence of HIV and Hepatitis B and C Viruses, South Africa. <i>Emerging Infectious Diseases</i> , 2017, 23, 1560-1563.	4.3	17
59	Real-Time Evolution of Zika Virus Disease Outbreak, Roatán, Honduras. <i>Emerging Infectious Diseases</i> , 2017, 23, 1360-1363.	4.3	17
60	Individual and hospital level correlates of red blood cell, platelet, and plasma transfusions among hospitalized children and neonates: a nationally representative study in the United States. <i>Transfusion</i> , 2020, 60, 1700-1712.	1.6	17
61	Preventing Transfusion-Transmitted Babesiosis. <i>Pathogens</i> , 2021, 10, 1176.	2.8	17
62	International Society of Blood Transfusion survey of experiences of blood banks and transfusion services during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2022, 117, 822-830.	1.5	17
63	A retrospective analysis of false positive infectious screening results in blood donors. <i>Transfusion</i> , 2016, 56, 457-465.	1.6	16
64	Perioperative Transfusions and Venous Thromboembolism. <i>Pediatrics</i> , 2020, 145, .	2.1	16
65	Transplant of SARS-CoV-2 infected Living Donor Liver: Case Report. <i>Transplantation Direct</i> , 2021, 7, e721.	1.6	16
66	International survey on the impact of parasitic infections: frequency of transmission and current mitigation strategies. <i>Vox Sanguinis</i> , 2019, 114, 17-27.	1.5	15
67	Financial analysis of large volume delayed sampling to reduce bacterial contamination of platelets. <i>Transfusion</i> , 2020, 60, 997-1002.	1.6	15
68	Kinetics of SARS-CoV-2 antibody responses pre-COVID-19 and post-COVID-19 convalescent plasma transfusion in patients with severe respiratory failure: an observational case-control study. <i>Journal of Clinical Pathology</i> , 2022, 75, 564-571.	2.0	15
69	Babesia microti and Malaria Infection in Africa: A Pilot Serosurvey in Kilosa District, Tanzania. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 51-56.	1.4	15
70	Funding blood safety in the 21st century. <i>Transfusion</i> , 2018, 58, 105-112.	1.6	14
71	Isohemagglutinin titering performed on an automated solid phase and hemagglutinin based analyzer is comparable to results obtained by manual gel testing. <i>Transfusion</i> , 2020, 60, 628-636.	1.6	14
72	Outcomes of SOT Recipients With COVID-19 in Different Eras of COVID-19 Therapeutics. <i>Transplantation Direct</i> , 2022, 8, e1268.	1.6	14

#	ARTICLE	IF	CITATIONS
73	The impact of human immunodeficiency virus infection on obstetric hemorrhage and blood transfusion in South Africa. <i>Transfusion</i> , 2015, 55, 1675-1684.	1.6	13
74	Residual risk of bacterial contamination: what are the options?. <i>Transfusion</i> , 2017, 57, 2289-2292.	1.6	13
75	Blood Product Utilization Among Trauma and Nontrauma Massive Transfusion Protocols at an Urban Academic Medical Center. <i>Anesthesia and Analgesia</i> , 2017, 125, 967-974.	2.2	13
76	Risk factors for peripartum blood transfusion in South Africa: a case-control study. <i>Transfusion</i> , 2018, 58, 2149-2156.	1.6	13
77	How do I implement an outpatient program for the administration of convalescent plasma for COVID-19?. <i>Transfusion</i> , 2022, , .	1.6	13
78	The contribution of unsafe blood transfusion to human immunodeficiency virus incidence in sub-Saharan Africa: reexamination of the 5% to 10% convention. <i>Transfusion</i> , 2016, 56, 3121-3132.	1.6	12
79	<i>Borrelia burgdorferi</i> and <i>Borrelia miyamotoi</i> seroprevalence in California blood donors. <i>PLoS ONE</i> , 2020, 15, e0243950.	2.5	12
80	Pharmacokinetics of high-titer anti-SARS-CoV-2 human convalescent plasma in high-risk children. <i>JCI Insight</i> , 2022, 7, .	5.0	12
81	Adaptive immune responses in vaccinated patients with symptomatic SARS-CoV-2 Alpha infection. <i>JCI Insight</i> , 2022, 7, .	5.0	12
82	A rare, potentially life-threatening presentation of passenger lymphocyte syndrome. <i>Transfusion</i> , 2017, 57, 1262-1266.	1.6	11
83	A pilot serosurvey of <i>Babesia microti</i> in Chinese blood donors. <i>Vox Sanguinis</i> , 2018, 113, 345-349.	1.5	11
84	Blood Transfusion Safety in Low-Resourced Countries: Aspiring to a Higher Standard. <i>Annals of Internal Medicine</i> , 2020, 173, 482-483.	3.9	11
85	Malaria parasitemia among blood donors in Uganda. <i>Transfusion</i> , 2020, 60, 955-964.	1.6	11
86	Emerging Infections and Blood Safety in the 21st Century. <i>Annals of Internal Medicine</i> , 2016, 165, 57.	3.9	10
87	Status of hospital-based blood transfusion services in low-income and middle-income countries: a cross-sectional international survey. <i>BMJ Open</i> , 2022, 12, e055017.	1.9	10
88	How do we manage blood donors and recipients after a positive Zika screening result?. <i>Transfusion</i> , 2017, 57, 2077-2083.	1.6	9
89	Human Seroprevalence of Tick-Borne <i>Anaplasma phagocytophilum</i> , <i>Borrelia burgdorferi</i> , and <i>Rickettsia</i> Species in Northern California. <i>Vector-Borne and Zoonotic Diseases</i> , 2019, 19, 871-878.	1.5	9
90	Blood transfusion trends in the United States: national inpatient sample, 2015 to 2018. <i>Blood Advances</i> , 2021, 5, 4179-4184.	5.2	9

#	ARTICLE	IF	CITATIONS
91	Male microchimerism in peripheral blood leukocytes from women with multiple sclerosis. <i>Chimerism</i> , 2011, 2, 6-10.	0.7	9
92	Imaging of an Invasive Malignant Thymoma on PET Scan: CT and Histopathologic Correlation. <i>Clinical Nuclear Medicine</i> , 2006, 31, 614-616.	1.3	8
93	Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. <i>Transfusion</i> , 2020, 60, 1243-1252.	1.6	8
94	Lessons learned in the collection of convalescent plasma during the COVID-19 pandemic. <i>Vox Sanguinis</i> , 2021, 116, 872-879.	1.5	8
95	In vivo characterization of emerging SARS-CoV-2 variant infectivity and human antibody escape potential. <i>Cell Reports</i> , 2021, 37, 109838.	6.4	8
96	Severe Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in Blood Donor Populations. <i>Journal of Infectious Diseases</i> , 2022, 225, 1-4.	4.0	8
97	Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2. <i>Transfusion Medicine Reviews</i> , 2022, 36, 125-132.	2.0	8
98	A Cross-Sectional Pilot Study of Blood Utilization in 27 Hospitals in Northern California. <i>American Journal of Clinical Pathology</i> , 2014, 142, 498-505.	0.7	7
99	One-unit compared to two-unit platelet transfusions for adult oncology outpatients. <i>Vox Sanguinis</i> , 2019, 114, 517-522.	1.5	7
100	Secondary bacterial culture of platelets to mitigate transfusion-associated sepsis: A 3-year analysis at a large academic institution. <i>Transfusion</i> , 2020, 60, 2021-2028.	1.6	7
101	Bacterial contamination of blood products in Africa. <i>Transfusion</i> , 2021, 61, 767-780.	1.6	7
102	COVID-19 and the impact on blood availability and transfusion practices in low- and middle-income countries. <i>Transfusion</i> , 2022, 62, 336-345.	1.6	7
103	Therapeutic plasma exchange for the treatment of refractory necrotizing autoimmune myopathy. <i>Journal of Clinical Apheresis</i> , 2022, 37, 253-262.	1.3	7
104	The Mirasol Evaluation of Reduction in Infections Trial (MERIT): study protocol for a randomized controlled clinical trial. <i>Trials</i> , 2022, 23, 257.	1.6	7
105	Therapeutic plasma exchange for hyperviscosity syndrome secondary to high rheumatoid factor. <i>Transfusion and Apheresis Science</i> , 2018, 57, 225-227.	1.0	6
106	The Babesia observational antibody (BAOBAB) study: A cross-sectional evaluation of Babesia in two communities in Kilosa district, Tanzania. <i>PLoS Neglected Tropical Diseases</i> , 2019, 13, e0007632.	3.0	6
107	International survey of strategies to mitigate transfusion-transmitted <i>Trypanosoma cruzi</i> in endemic countries, 2016-2018. <i>Vox Sanguinis</i> , 2022, 117, 58-63.	1.5	6
108	Risk of transfusion-transmitted <i>Babesia microti</i> in Canada. <i>Transfusion</i> , 2021, 61, 2958-2968.	1.6	6

#	ARTICLE	IF	CITATIONS
109	A Hemagglutination-Based Semiquantitative Test for Point-of-Care Determination of SARS-CoV-2 Antibody Levels. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0118621.	3.9	6
110	Zika Virus: Knowledge Assessment of Residents and Health-Care Providers in Roatan, Honduras, following an Outbreak. <i>American Journal of Tropical Medicine and Hygiene</i> , 2018, 99, 211-215.	1.4	6
111	Experience with COVID-19 convalescent plasma provides vital guidance to future pandemics. <i>Transfusion</i> , 2022, 62, 681-684.	1.6	6
112	Antibody attributes that predict the neutralization and effector function of polyclonal responses to SARS-CoV-2. <i>BMC Immunology</i> , 2022, 23, 7.	2.2	6
113	Coronavirus Disease 2019 Convalescent Plasma and the Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Titer. <i>Journal of Infectious Diseases</i> , 2021, 223, 740-742.	4.0	5
114	A review of the use of blood and blood products in HIV-infected patients. <i>Southern African Journal of HIV Medicine</i> , 2012, 13, 87-104.	0.9	5
115	Biannual Treatment of Preschool Children with Single Dose Azithromycin to Reduce Mortality: Impact on Azithromycin Resistance in the MORDOR Trial in Tanzania. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1301-1307.	1.4	5
116	Differentiation of Individuals Previously Infected with and Vaccinated for SARS-CoV-2 in an Inner-City Emergency Department. <i>Journal of Clinical Microbiology</i> , 2022, 60, jcm0239021.	3.9	5
117	A cross-sectional study of peripartum blood transfusion in the Eastern Cape, South Africa. <i>South African Medical Journal</i> , 2016, 106, 1103.	0.6	4
118	Filariasis and transfusion-associated risk: a literature review. <i>Vox Sanguinis</i> , 2021, 116, 741-754.	1.5	4
119	Pathology Residency Program Special Expertise Tracks Meet the Needs of an Evolving Field. <i>Academic Pathology</i> , 2021, 8, 23742895211037034.	1.1	4
120	A Cross-Sectional Study of the Availability of Azithromycin in Local Pharmacies and Associated Antibiotic Resistance in Communities in Kilosa District, Tanzania. <i>American Journal of Tropical Medicine and Hygiene</i> , 2019, 100, 1105-1109.	1.4	4
121	Microchimerism in the transfused obstetric population. <i>Vox Sanguinis</i> , 2014, 107, 428-430.	1.5	3
122	The impact on malaria of biannual treatment with azithromycin in children age less than 5 years: a prospective study. <i>Malaria Journal</i> , 2019, 18, 284.	2.3	3
123	Morbidity in a Longitudinal Cohort of Children Residing in Villages Randomized to Biannual Treatment With Azithromycin Versus Placebo. <i>Clinical Infectious Diseases</i> , 2020, 70, 574-580.	5.8	3
124	Comparative changes of preoperative autologous transfusions and perioperative cell salvage in the United States. <i>Transfusion</i> , 2020, 60, 2260-2271.	1.6	3
125	Cryoprecipitate Utilization Patterns Observed With a Required Prospective Approval Process vs Electronic Dosing Guidance. <i>American Journal of Clinical Pathology</i> , 2020, 154, 362-368.	0.7	3
126	Blood transfusions in gunshot-wound-related emergency department visits and hospitalizations in the United States. <i>Transfusion</i> , 2021, 61, 2277-2289.	1.6	3



#	ARTICLE	IF	CITATIONS
127	Mortality and Associated Comorbidities Among Patients Hospitalized for Deep Vein Thrombosis and Pulmonary Embolism in the United States: Results from a Nationally Representative Database. <i>Blood</i> , 2020, 136, 39-40.	1.4	3
128	Associated comorbidities, healthcare utilization & mortality in hospitalized patients with haemophilia in the United States: Contemporary nationally representative estimates. <i>Haemophilia</i> , 2022, , .	2.1	3
129	<i>Babesia</i> screening: the importance of reporting and calibration in cost-effectiveness models. <i>Transfusion</i> , 2016, 56, 774-775.	1.6	2
130	Antenatal blood transfusion in South Africa: indications and practice in a high-HIV prevalence setting. <i>Transfusion</i> , 2020, 60, 479-487.	1.6	2
131	Implementation outcomes of policy and programme innovations to prevent obstetric haemorrhage in low- and middle-income countries: a systematic review. <i>Health Policy and Planning</i> , 2020, 35, 1208-1227.	2.7	2
132	Impact of Biannual Azithromycin on Anemia in Preschool Children in Kilosa District, Tanzania: A Cluster-Randomized Clinical Trial. <i>American Journal of Tropical Medicine and Hygiene</i> , 2020, 103, 1311-1314.	1.4	2
133	Powassan virus: What is the risk to the blood supply?. <i>Transfusion</i> , 2021, 61, 3286-3288.	1.6	2
134	Implementation of national blood conservation recommendations at an adult sickle cell center. <i>Transfusion</i> , 0, , .	1.6	2
135	A GBS culture collected shortly after GBS prophylaxis may be inaccurate. <i>Journal of Maternal-Fetal and Neonatal Medicine</i> , 2012, 25, 736-738.	1.5	1
136	Patient Blood Management. , 2017, , 105-133.		1
137	A risk-based decision-making framework for blood safety: what's the case for Zika?. <i>ISBT Science Series</i> , 2020, 15, 31-39.	1.1	1
138	Low rates of transfusion-transmitted infection screening in chronically transfused adults with sickle cell disease. <i>Transfusion</i> , 2021, 61, 2421-2429.	1.6	1
139	526: A GBS culture collected after antibiotic administration may be inaccurate. <i>American Journal of Obstetrics and Gynecology</i> , 2008, 199, S154.	1.3	0
140	Capturing the passenger leukocyte. <i>Transfusion</i> , 2019, 59, 3291-3292.	1.6	0
141	Slower response to treatment of iron deficiency anaemia in pregnant women infected with HIV: a prospective cohort study. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2021, 128, 1674-1681.	2.3	0
142	Causes of death after biannual azithromycin treatment: A community-level randomized clinical trial. <i>PLoS ONE</i> , 2021, 16, e0250197.	2.5	0
143	Sequential dosing of convalescent COVID-19 plasma with significant temporal clinical improvements in a persistently SARS-COV-2 positive patient. <i>Transfusion and Apheresis Science</i> , 2021, 60, 103180.	1.0	0
144	Blood Product (Donor) Noninfectious and Infectious Testing and Modification. <i>Clinics in Laboratory Medicine</i> , 2021, 41, 579-598.	1.4	0

#	ARTICLE	IF	CITATIONS
145	The feasibility of multiple units of convalescent plasma in mechanically ventilated patients with COVID-19: A pilot study. <i>Transfusion and Apheresis Science</i> , 2022, , 103423.	1.0	0
146	<i>Borrelia burgdorferi</i> and <i>Borrelia miyamotoi</i> seroprevalence in California blood donors. , 2020, 15, e0243950.		0
147	<i>Borrelia burgdorferi</i> and <i>Borrelia miyamotoi</i> seroprevalence in California blood donors. , 2020, 15, e0243950.		0
148	<i>Borrelia burgdorferi</i> and <i>Borrelia miyamotoi</i> seroprevalence in California blood donors. , 2020, 15, e0243950.		0
149	<i>Borrelia burgdorferi</i> and <i>Borrelia miyamotoi</i> seroprevalence in California blood donors. , 2020, 15, e0243950.		0
150	Differential antibody production by symptomatology in SARS-CoV-2 convalescent individuals. <i>PLoS ONE</i> , 2022, 17, e0264298.	2.5	0